

Liver fibrosis

Ramón Bataller, David A. Brenner

J Clin Invest. 2005;115(4):1100-1100. <https://doi.org/10.1172/JCI24282C1>.

Corrigendum

Original citation: *J. Clin. Invest.* 115:209–218(2005). doi:10.1172/JCI24282 Citation for this corrigendum: *J. Clin. Invest.* 115:1100 (2005). doi:10.1172/JCI24282C1 PPAR γ agonists but not PPAR antagonists, as listed in Table 2, have shown inhibitory effects on HSCs and antifibrotic effects in animal models with liver fibrosis and patients with NASH. The authors regret the error.

Find the latest version:

<https://jci.me/24282C1/pdf>





Corrigendum

Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a *MYO5A* F-exon deletion (GS1)

Gaël Ménasché, Chen Hsuan Ho, Ozden Sanal, Jérôme Feldmann, Ilhan Tezcan, Fügen Ersoy, Anne Houdusse, Alain Fischer, and Geneviève de Saint Basile

Original citation: *J. Clin. Invest.* **112**:450–456 (2003). doi:10.1172/JCI200318264.

Citation for this erratum: *J. Clin. Invest.* **115**:1100 (2005). doi:10.1172/JCI200518264C1.

During preparation of this manuscript for publication, an error was introduced into the first sentence of Methods regarding numbering of the 2 patients. The sentence should read:

The clinical presentation of patients A and B (PA and PB) has been previously reported (P13 and P12, respectively, in ref. 18).

The authors regret this error.

Corrigendum

Toll-like receptor 9–induced type I IFN protects mice from experimental colitis

Kyoko Katakura, Jongdae Lee, Daniel Rachmilewitz, Gloria Li, Lars Eckmann, and Eyal Raz

Original citation: *J. Clin. Invest.* **115**:695–702 (2005). doi:10.1172/JCI200522996.

Citation for this corrigendum: *J. Clin. Invest.* **115**:1100 (2005). doi:10.1172/JCI200522996C1.

Reference number 24 was incorrect. The corrected reference should read:

Ishii, K.J., et al. 2002. Potential role of phosphatidylinositol 3 kinase, rather than DNA-dependent protein kinase, in CpG DNA-induced immune activation. *J. Exp. Med.* **196**:269–274.

The authors regret this error.

Corrigendum

Liver fibrosis

Ramón Bataller and David A. Brenner

Original Citation: *J. Clin. Invest.* **115**:209–218 (2005). doi:10.1172/JCI200524282.

Citation for this corrigendum: *J. Clin. Invest.* **115**:1100 (2005). doi:10.1172/JCI200524282C1.

PPAR γ agonists but not PPAR antagonists, as listed in Table 2, have shown inhibitory effects on HSCs and antifibrotic effects in animal models with liver fibrosis and patients with NASH.

The authors regret this error.